The Digestive Disease Week annual meeting, sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, and Society for Surgery of the Alimentary Tract, was held from May 18 to 21 in Orlando, Fla., and attracted approximately 16,000 participants from around the world, including researchers and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference featured thousands of abstracts and hundreds of lectures highlighting recent advances in gastroenterology research, medicine, and technology

Advances in IBD evaluation, management to be re-viewed.

回顾IBD评估管理方面的进展

“Often when you go to a talk, you see highlights of one technique or technology that has been introduced recently,” Dr. Liu said. “In this session, GIs will have a chance to review all the advances in IBD management related to endoscopy.”

“Increasingly, endoscopic tools are being developed to predict disease outcome, particularly aggressive disease,” she said. “A list of endoscopic prognosticators for patients will be reviewed.”
“Detection of dysplasia in IBD is an important area and Dr. Kiesslich, who is a well-known expert in the field, will discuss the optimal techniques for dysplasia detection,” Dr. Liu said.

TNF-alpha antagonists becoming more accepted for IBD treatment
肿瘤坏死因子拮抗剂越来越被IBD治疗接受

“The treatment paradigm for IBD has changed,” said Brian Feagan. “The traditional approach has been to try treatments sequentially and hope that something eventually works. Today, we risk-stratify patients and those with the worst prognosis receive the most effective therapy early in the course of the disease. That is quite an important shift in thinking about the management of the disease.”
“We are at the stage where TNF antagonists have really moved from experimental therapy to a treatment of last resort to mainstream therapy,” he said. “This shift
in treatment is an important process.”But the change has been neither fast
nor easy, Dr. Feagan acknowledged.
Dr. Feagan said every clinician who treats IBD patients should attend the Cochrane IBD Symposium. “This symposium will synthesize the data and the arguments that are already out there,”he said. “We hope to provide a view from 50,000 feet of these therapies that clinicians don’t always have the luxury of sitting back and taking in.”

Expert examines liver disease in children with IBD
探讨IBD患儿合并肝病的情况

Dennis D. Black, MD, reviewed the various causes of liver disease in children with inflammatory bowel disease （IBD） and research into its treatment.
The possible causes of an abnormal test include drug-induced hepatotoxicity, autoimmune liver disease, steatosis, cholelithiasis, portal or hepatic vein thrombosis, hepatosplenic T-cell lymphoma, or abscess, said Dr. Black
Treatment with corticosteroids with or without azathioprine results in remission in
about 80 percent of patients, Dr. Black said.
“We really need multicenter collaborative studies of children with IBD to focus on liver disease, guide therapy and provide prognosis,” Dr. Black concluded.

Expert panel addresses complications after IBD surgery
专家小组就IBD术后并发症发表谈话

“Recurrence is the rule after surgery for Crohn’s disease, so plan accordingly,” saidNeil Hyman.
The risk factors for recurrence of Crohn’s disease after ileal pouch anal anastomosis （IPAA） surgery include a patient history of smoking, penetrating phenotype disease, perianal disease, prior intestinal resection and extensive bowel resection, Dr. Hyman said.
Small-bowel obstruction is a common complication of IPAA surgery for ulcerativecolitis, as are pouchitis（about 40 percent of patients） and infertility （24 to 82 percent of patients）, he noted.
The treatment options for pouchitis include ciprofloxacin or metronidazole, steroids, 5-aminosalicylic acid medications, budesonide suppositories, and infliximab or azathioprine in exceptional cases, Dr. Hyman said.